Department of Ophthalmology, Wuhan Eyegood Ophthalmic, Wuhan, China.
Medicine (Baltimore). 2021 Apr 9;100(14):e25354. doi: 10.1097/MD.0000000000025354.
In the current literature, it is still controversial whether intravitreal aflibercept injection can provide better vision restoration compared with vitrectomy with panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) patients. Given that there is no high-quality meta-analysis or review to incorporate existing evidence, the purpose of this study is to systematically review the level I evidence in the literature to ascertain whether intravitreal aflibercept injection can provide better vision restoration compared with vitrectomy with PRP for PDR patients.
The systematic literature review is structured to adhere to PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-analyses), which include requirements deemed essential for the transparent reporting of results. A systematic search will be performed in Web of Science, Embase, Scopus, Science Direct, Cochrane Library up to and inclusive of March 19, 2021. The method of data extraction will follow the approach outlined by the Cochrane Handbook for Systematic Reviews of Interventions. The primary outcome is change in best-corrected visual acuity. The secondary outcomes are change in area of neovascularization and change in area of retinal nonperfusion. Where disagreement occurs, this will be resolved through discussion. All outcomes are pooled on random-effect model. A P value of < .05 is considered to be statistically significant.
The results of our review will be reported strictly following the PRISMA criteria.
The hypothesis of the study was that visual acuity recovery would be faster with vitrectomy because the blood is mechanically cleared during surgery.
10.17605/OSF.IO/NCAXW.
在当前的文献中,关于对于增生型糖尿病视网膜病变(PDR)患者,玻璃体内注射阿柏西普是否能比全视网膜光凝(PRP)联合玻璃体切除术提供更好的视力恢复,仍存在争议。鉴于没有高质量的荟萃分析或综述来整合现有证据,本研究旨在系统地回顾文献中的 I 级证据,以确定玻璃体内注射阿柏西普是否能比 PRP 联合玻璃体切除术为 PDR 患者提供更好的视力恢复。
系统文献综述的结构符合 PRISMA 指南(系统评价和荟萃分析的首选报告项目),包括对结果透明报告被认为是必不可少的要求。将在 Web of Science、Embase、Scopus、Science Direct、Cochrane Library 中进行系统搜索,截至并包括 2021 年 3 月 19 日。数据提取方法将遵循 Cochrane 干预系统评价手册中概述的方法。主要结局是最佳矫正视力的变化。次要结局是新生血管面积的变化和视网膜无灌注面积的变化。如果出现分歧,将通过讨论解决。所有结局都采用随机效应模型进行汇总。P 值<.05 被认为具有统计学意义。
我们的综述结果将严格按照 PRISMA 标准报告。
该研究的假设是,玻璃体切除术的视力恢复会更快,因为手术过程中血液会被机械清除。
10.17605/OSF.IO/NCAXW。